Clinical Trials Logo

B Cell Leukemia clinical trials

View clinical trials related to B Cell Leukemia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05095155 Completed - Lymphoma Clinical Trials

Study of the Prognostic Role of Gene Polymorphism in the Development of B-cell Leukemias and Lymphomas in Children of Kazakh Nationality

Start date: April 1, 2022
Phase:
Study type: Observational

To search for a genetic marker of B-cell leukemias and lymphomas in children of Kazakh nationality, a single nucleotide polymorphism (SNP) analysis of DNA obtained from the peripheral blood of patients with B-cell leukemias and lymphomas in children of Kazakh nationality and normal control will be performed.

NCT ID: NCT04260945 Completed - B-cell Leukemia Clinical Trials

CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients

Start date: March 10, 2020
Phase: Phase 1
Study type: Interventional

This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of CD19/CD20 Dual-CAR-T cells in patients with refractory and relapsed B-cell leukemia.

NCT ID: NCT03068416 Completed - B-Cell Lymphoma Clinical Trials

CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy

Start date: September 18, 2017
Phase: Phase 2
Study type: Interventional

Treatment of patients with B cell lymphoma or leukemia with two doses of CD19-targeting chimeric antigen receptor (CAR) T cells to evaluate for safety and efficacy.

NCT ID: NCT02132624 Completed - B Cell Lymphoma Clinical Trials

CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.

Start date: April 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Chimeric antigen receptor (CAR) T cells targeting CD19 will be evaluated for safety and efficacy in patients with B cell lymphoma or leukemia. The CAR consists of a CD19 targeting antibody scFv with three intracellular signaling domains derived from CD3 zeta, CD28 and 4-1BB. Autologous T cells will be gene engineered with the CAR gene using a retrovirus vector. Prior to T cell infusion, the patients will be subjected to preconditioning treatment. After T cell infusion, the patients will be evaluated for 24 months for adverse reactions, persistence of CAR T cells and efficacy.

NCT ID: NCT01626495 Completed - B Cell Lymphoma Clinical Trials

Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma

Pedi CART19
Start date: August 17, 2011
Phase: Phase 1/Phase 2
Study type: Interventional

This is a study for children who have been previously treated for Leukemia/Lymphoma. In particular, it is a study for people who have a type of Leukemia/Lymphoma that involves B cells (a type of white cell), which contain the cancer. This is a new approach for treatment of Leukemia/Lymphoma that involves B cells (tumor cells). This study will take the subject's white blood cells (T cells) and modify them in order to target the cancer. The subject's T cells will be modified in one or two different ways that will allow the cells to identify and kill the tumor cells (B cells). Both ways of modifying the cells tells the T cells to go to the B cells (tumor cells) and turn "on" and potentially kill the B cells (tumor cells). The modification is a genetic change to the T cells, or gene transfer, in order to allow the modified T cells to recognize your tumor cells but not other normal cells in the subject's body. These modified cells are called chimeric antigen receptor 19 (CART19) T-cells.

NCT ID: NCT00849654 Completed - B-Cell Lymphoma Clinical Trials

Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma

PCYC-04753
Start date: February 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to establish the safety and optimal dose of orally administered PCI-32765 in patients with recurrent B cell lymphoma.

NCT ID: NCT00230282 Completed - Leukemia Clinical Trials

Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia

Start date: July 2004
Phase: Phase 2
Study type: Interventional

The primary objective of this study was to evaluate the safety and efficacy of the combination of fludarabine and cyclophosphamide in previously untreated CLL patients. Participants will receive fludarabine and cyclophosphamide on days 1, 2, and 3 of six 28-day cycles.